Mesa Tech International, Inc. (MTI) seeks to commercialize technologies to reduce the complexity and cost of nucleic acid-based molecular diagnostics (MDx). MTI’s goal is to replace complex, time-consuming and expensive laboratory-based MDx tools. MTI’s proprietary and patented technology, already implemented in working prototypes, yields tremendous cost, time and complexity reductions for MDx that allow such tests to be completed within 30 minutes at the point-of-care (POC) and without need to send samples to any outside laboratory.
The MTI platform includes easy-to-use, inexpensive handheld units and disposable reagent cards, which will make MDx-based infectious disease and cancer screening far more accessible and affordable to diverse end-users and which will open huge new markets.
Initially, these products will be sold to physicians and physician assistants for use in offices, clinics and hospitals. Eventually, MDx in MTI formats could even become available to individual consumers at home, making such molecular tests as common as today’s widely used home pregnancy.
